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Bakground: The objective of this study was to determinate the prevalence of chronic kidney disease (CKD) and the
different stages of CKD in patients with type 2 diabetes mellitus (DM2) treated in primary care consults in Spain.
Methods: A national cross-sectional study was performed in primary care consults. The following data were
collected: demographic and anthropometric information; list of present cardiovascular risk factors (CVRF); previous
macrovascular and microvascular disease history; physical examination and analytical data from the previous
12 months, including the urine albumin-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) to
evaluate renal function.
Results: With regard to the patients, 27.9% presented some degree of CKD as follows: 3.5% with stage 1; 6.4% with
stage 2; 16.8% with stage 3 (11.6% with stage 3A and 5.2% with stage 3B); and 1.2% with stages 4 and 5. The
prevalence of patients with UACR ≥ 30 mg/g was 15.4% (13% microalbuminuria and 2.4% macroalbuminuria). Renal
impairment (RI) was found in 206 patients (18%) of whom 133 patients (64.6%) was stage 3A, 60 patients (29.1%)
was stage 3B and 13 patients (6.3%) stages 4 and 5. Among patients with RI, 143 patients (69.4%) had
normoalbuminuria.
The following variables were significantly associated with CKD: age; sex (women); systolic arterial blood pressure
(SABP) ≥ 150 mmHg; and a previous history of cardiovascular disease.
Conclusions: The results showed that the prevalence for any type of CKD was 27.9%. A systematic determination
of UACR and eGFR may contribute to an early diagnosis, thus allowing intervention during the initial stages of the
disease when treatment is more efficient.
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Chronic kidney disease (CKD) is considered an import-
ant public health problem [1], as it increases the mortal-
ity risk for any cause, which increases the frequency of
cardiovascular disease episodes and the progression to
end-stage renal disease (ESRD) independently of trad-
itional CVRF [2-5].
Diabetes mellitus (DM) is one of the leading causes
of CKD and is recognised as one of the leading causes of
ESRD in the United States [6]. Approximately 40% of
the adult population diagnosed or not diagnosed with* Correspondence: gabriel.coll@ias.scs.es
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distribution, and reproduction in any mediumDM has some degree of CKD in the United States. CKD
increases the cost of managing DM [7]. CKD commonly
initiates at the prediabetes stage due to its coexistence
with other CVRF, and CKD is present in one-third of
DM2 patients [8].
Annual screening for CKD in DM2 patients, including
the UACR and eGFR, is recommended at the moment of
disease diagnosis. Early identification of CKD would allow
immediate intervention, thus diminishing the progression
of renal disease and cardiovascular risk. Chronic Kidney
Disease include diminished eGFR and/or increased UACR,
although a considerable percentage of DM2 patients pre-
sent reduced eGFR without increased UACR [9].
The guidelines provided by the National Kidney
Foundation (NKF) for the evaluation, classification,Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Quality Initiative (KDOQI) [10] define the following as diag-
nostic criteria for CKD: a eGFR value below 60 ml/min/
1.73 m2 in a time period equal or superior to three months
or the presence of renal lesion with or without reduced GFR
in a time period equal or superior to three months. The
concept of renal lesion is defined as the presence of
structural or functional alterations of the kidney detected
directly by histological alteration in the renal biopsy or
indirectly by an UAE increase, alterations in the urine
sediment, or differences identified with imaging techniques.
The combination of these clinical criteria is the basis for the
classification of CKD in five stages.
The objective of this study was to establish the preva-
lence of CKD and the different stages of CKD in patients
with DM2 treated in primary care consults in Spain.
Methods
Study design and population
This study was a national cross-sectional study performed
in primary care consults. Estimating a higher prevalence
of chronic kidney disease in women than in men, and
higher in those over 64 years, there was a proportional
stratified sampling. A sample size of 1153 patients was
calculated assuming a 0.05 alpha error and 2.5% precision
for an estimated prevalence of 25%. Foreseeing a 20% loss
due to erroneous or incomplete data, the size of the sam-
ple was increased to 1383 patients. During the recruit-
ment, 1279 patients were included in the study, but 134
(10.4%) patients were discarded because of incomplete or
erroneous data. To rule out a bias attributable to patients
discarded we compared each other groups, of all variables
compared did not show differences. The total number of
valid patients for the final analysis was 1145. The patients
included both genders and were over 40 years old. More-
over, the patients were diagnosed with DM2, and they
had all of the variables necessary for the study included in
their clinical history. Each researcher included 15 patients
who met the inclusion criteria, a maximum of 3 patients
per day. The patients were selected by convenience sam-
ple of the first 3 DM2 patients each day who came to the
consult for any reason and met the inclusion criteria until
complete the number of participants per researcher.
The information for each participant was collected in the
period from February to July 2011. The Ethical and Clinical
Investigation Committee of the Institut d’ Assistència
Sanitària (IAS) in Salt, Girona, Spain approved the study.
To obtain the necessary data for this study from the
clinical history of patients, all participants provided writ-
ten informed consent.
Variables and procedure
The following variables were collected during the visit:
age, gender, ethnicity, weight, height, body mass index(BMI) was calculated as weight in kilograms divided in
meters squared; obesity was defined as BMI ≥ 30 kg/m2,
abdominal waist circumference, CVRF. Cardiovascular
diseases (CVD) was collected through the medical re-
cord as a history of Stroke (ischaemic cerebrovascular
disease) included only symptomatic brain infarction, and
did not include silent brain infarction, transient ischae-
mic attack or brain haemorrhage. CHD included a pre-
vious history of myocardial infarction, angina pectoris,
the presence of coronary interventions or the presence
of ECG abnormalities suggestive of CHD. PAD was
diagnosed by an ankle-brachial pressure index of < 0.9
and/or two absent foot pulses. Diabetes mellitus was
defined as fasting glucose ≥ 126 mg/dL or non-fasting
glucose ≥ 200 mg/dL or use of glucose-lowering drugs.
Hypertension was defined as SBP of 140 mmHg or greater,
DBP of 90 mmHg or greater, or use of antihypertensive
medications irrespective of BP. Hyperlipidemia was defined as
total cholesterol≥ 250 mg/dL, LDL cholesterol > 155 mg/dL,
HDL cholesterol < 40 mg/dL in men and < 48 mg/dL in
women, trigycreides > 150 mg/dL or pharmacologig
lipid lowering treatment. Cigarette smoking was defined
as never/past/current.
The following clinical and analytical measurements
were collected: DM2 duration, arterial pressure (average
of the last three determinations), drugs taken by the
patient at the time the data were collected (antidia-
betic, antihypertensives, hypolipemiant, antiplatelet, and
anticoagulants). Basal glycaemia, glycosylated haemoglo-
bin (HbA1c), plasmatic haemoglobin, total cholesterol,
LDL cholesterol, HDL cholesterol, non-HDL cholesterol,
triglycerides, serum creatinine after overnight fasting for
at least 12 hr, and the urine albumin-creatinine ratio
(UACR) in a urine sample collected in the first morning
urine specime, using the most recent value of the last
12 months. The analysis determination was not performed
by a single laboratory.
In this study, the presence of CKD was based on
KDOQI [10] criteria as follows: patients with GFR
< 60 ml/min/1.73 m2 or the presence of renal damage
if UACR values were elevated (UACR ≥ 30 mg/g). Con-
sidering that all of the values for serum creatinine were
measured using the modified kinetic method of Jaffe, the
MDRD-IDMS (Modification of Diet in Renal Disease
study- isotope dilution mass spectrometry) equation [11]
was used to calculate the GFR. Albuminuria was defined
as a UACR of 30 mg/g or more. Microalbuminuria was
defined as a UACR ranging from 30 to 299 mg/g, and
macroalbuminuria was defined as a UACR of 300 mg/g or
more. CKD was defined as the presence of albuminuria or
eGFR < 60 mL/min/1.73 m2. Stages of CKD were defined
as follows: stage 1 (eGFR ≥ 90 mL/min/1.73 m2 and
UACR ≥30 mg/g); stage 2 (eGFR 60–89 mL/min/1.73 m2
and UACR ≥30 mg/g); stage 3 (eGFR 30–59 mL/min/1.73 m2
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regardless of UACR); and stage 5 (eGFR <15 mL/min/
1.73 m2 regardless of UACR). Two of three determinations of
eGFR or/and UACR, in a period of three or more
months, should be presented normal or altered values.
The cases that did not fulfil this requisite were
excluded from the final analysis of the study. The same re-
quirement of two or more measurement in three months
was applied to a classification of presence CKD or absence
CKD (“no CKD”).
Statistical analysis
Measurements of central tendency and dispersion were
used to perform a descriptive analysis of the quantita-
tive variables studied. Absolute and relative frequencies
were used for qualitative variables. The global CKD
prevalence was calculated, and the CKD prevalence of
each stage was also calculated. Age group and sex
stratified the results. Bivariate analysis of contrastingTable 1 Clinical and metabolic characteristics of participants
Total
N (%) 1.145
Age (years) 66.8 ± 11.3
Duration diabetes (years) 9.1 ± 6.7
BMI (kg/m2) 30.3 ± 5.2
Obesity, n(%) 533 (46,5)





HbA1C (%) 7.3 ± 1.3
Hypertension (n%) 860 (75.1)
Systolic Blood Pressure (mmHg) 134.5 ± 13.2
Diastolic Blood Pressure (mmHg) 77.0 ± 9.1
Total cholesterol (mmol/L) 4.70 ± 0.93
LDL cholesterol (mg/dl) 2.79 ± 0,83
non-HDL cholesterol (mg/dl) 3.49 ± 0,91
HDL cholesterol (mg/dl) 1.29 ± 0.35
Triglycerides (mg/dl) 1.69 ± 0.96
Plasmatic creatinine (mg/dl) 0.93 ± 0.3
eGFR ml/min/1,73 m2 79.9 ± 23.5
Albumin/creatinine ratio (mg/g) 39.2 ± 144.3
Coronary heart disease (n%) 177 (15.4)
Heart failure (n%) 91 (7.9)
Peripheral vascular disease (n%) 98 (8.5)
Stroke (n%) 79 (6.9)
BMI = Body Mass Index. HbA1C = glycosilated hemoglobin. eGFR = estimated glomer
cholesterol = High Density Lipoprotein cholesterol.hypotheses was used to establish the presence of sta-
tistically significant differences in the clinical char-
acteristics of the patients depending on the presence
or absence of CKD and its stage. Proportion compari-
son was performed by means of a Chi-squared test with
Yates correction when it was considered necessary. The
means of the clinical and analytical variables were
compared with the ANOVA test and the medians were
compared with the the Kruskal-Wallis test depending
on the distribution of the data. The normal distribution
of continuous variables was contrasted with the Shapiro-
Wilk test. The Bonferroni correction was used for
multiple testing. The association degree between the
demographic and clinical characteristics of the patients
and the presence or absence of CKD was established with
a binomial logistic regression. The results were expressed
as absolute numbers, percentages, medians, standard
deviations, odd ratios, and CI of 95%. Statistical signifi-
cance was set at 0.05 when contrasting hypotheses. DataMen Women P
689 (60.2%) 456 (39.8%)
66.3 ± 11.4 67.4 ± 10.9 0.089
8.8 ± 6.5 9.4 ± 6.9 0.250
29.6 ± 4.5 31.1 ± 6.0 0.001
297 (43.1) 236 (51.8) 0.004
103.5 ± 12.1 100.2 ± 13.6 0.001
123 (17.9) 35 (7.7) 0.001
312 (45.2) 33 (7.2)
254 (36.9) 388 ( 85.1)
7.2 ± 1.2 7.3 ± 1.3 0.089
514 (74.6) 346 (75.9) 0.625
134.3 ± 12.6 134.8 ± 14,0 0.984
77.1 ± 8.9 76.8 ± 9.3 0.477
4.63 ± 0.99 4.89 ± 0.90 0.001
2.74 ± 0,86 2.84 ± 0,78 0.021
3.46 ± 0,96 3.55 ± 0,90 0.086
1.17 ± 0.31 1.33 ± 0.37 0.001
1.70 ± 1.04 1.68 ± 0.87 0.450
1.01 ± 0.3 0.8 ± 0.2 0.001
80.4 ± 22.4 78.6 ± 23.6 0.142
46.3 ± 169.5 28.4 ± 93.4 0.979
137 (19.9) 34 (7.5) 0.001
49 (7.1) 42 (9.2) 0.199
85 (12.3) 13 (2.9) 0.001
57 (8.3) 22 (4.8) 0.024
ular filtration rate. LDL cholesterol = Low Density Lipoprotein cholesterol. HDL
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14.0 statistical program for Windows.
Results
Table 1 shows the clinical and demographic characteristics
of the 1145 participants. When comparing men and wo-
men, no significant differences were detected with age,
HbA1c levels, and arterial pressure. Men presented higher
values for creatinine, because men have more muscle mass
than women, and smoking than women. Total cholesterol
levels and HDL cholesterol were higher in women than
in men. The prevalence of coronary disease, ictus, and
peripheral vascular disease was higher in men than in
women.
Table 2 shows the prevalence of the different types of
kidney disease. Prevalence of CKD in patients was 27.9%
(CI 95% = 25.2 - 30.5), and the CKD prevalence was
classified into the following stages: 3.5% with stage 1
(CI 95% = 2.3 - 4.6); 6.4% with stage 2 (CI 95% = 4.9 - 7.8);
16.8% with stage 3 (CI 95% = 14.6 - 19.0), including
11.6% with stage 3A (CI 95% = 9.7 - 13.5) and 5.2% with
stage 3B (CI 95% = 3.9 - 6.5); and 1.2% with stages 4
and 5 (CI 95% = 0.4 - 1.7). Due to their low prevalence,
stages 4 and 5 were analysed together. Prevalence for
UACR ≥ 30 mg/g was 15.4% (CI 95% = 13.2 - 17.5),
microlbuminuria 13% (CI 95% = 11.1 - 15), and
macroalbuminuria 2.4% (CI 95% = 1.4 - 3.2). Renal im-
pairment (RI) (eGFR <60) was found in 206 patients
(18%) of whom 133 patients (64.6%) was stage 3A, 60
patients (29.1%) was stage 3B and 13 patients (6.3%)
stages 4 and 5. Among patients with RI, 143 patients
(69.4%) had normoalbuminuria.
The comparison of diabetic patients with CKD vs
diabetic patients with no CKD showed no significant dif-
ference in their sex, BMI, weight, systolic arterial bloodTable 2 Prevalence of different types of chronic kidney disea
eGFR, Normoalbuminuria
mL/min per 1.73 m2 ACR < 30 mg/g
≥ 90 (Stage 1) 298 (26%)
60-89.9 (Stage 2) 528 (46.1%)
45-59.9 (Stage 3A) 99 (8.65%)
30–44.9 (Stage 3B) 40 (3.5%)
< 30 (Stages 4–5) 4 (0.35%)
UACR Normoalbuminuria
N (%) 969 (84.6%)
eGFR≥ 60
mL/min per 1.73 m2 939 (82%)
eGFR < 60
mL/min per 1.73 m2 206 (18%)
Any type of CKD 319 (27.9%)
eGFR = estimated glomerular filtration rate. ACR = albumin-creatinine ratio. CKD = Chpressure (SABP), diastolic arterial blood pressure (DABP),
tobacco use, or lipid profile values. No significant dif-
ferences between the groups were found when comparing
DM2 duration or glycaemia levels. However, diabetic
patients with CKD had higher HbA1c values than dia-
betic patients without CKD. Diabetic patients with CKD
had elevated creatinine values. Creatinine values, in CKD
patients, increased as the disease progressed. Age was sig-
nificantly correlated with CKD with increasing percentages
of elderly patients in the most advanced stages. Patients
diagnosed with arterial hypertension had a higher CKD
prevalence (Table 3).
The multivariate analysis by binomial logistic regres-
sion demonstrated that CKD was significantly associated
with age. Older age was associated with higher CKD
prevalence among women if SABP ≥ 150 mm Hg. Even
at SAP ≥ 140 mm Hg, an increased CKD prevalence was
observed. A previous clinical history of ischemic cardiac
disease, cardiac insufficiency, or peripheral vascular dis-
ease was significantly associated with increased CKD
prevalence (Table 4).
Discussion
To the best of our knowledge, this study was the first epi-
demiological investigation on CKD prevalence using the
KDOQI criteria on Spanish patients attending primary
care consults. Different studies have been performed in
Spain on IR prevalence in DM2 patients [12-15]. The
study by Lou Arnal et al. [16] has been the only report
published on CKD prevalence in DM2 patients in primary
care consults, and their study was performed with only
one UACR measurement in Alcañiz, Teruel, Spain. The
results of the PERCEDIME2 study showed an elevated
CKD prevalence in DM2 patients in primary care consults
in Spain. DM2 patients with CKD, 18% had a eGFRse in Spain
Microalbuminuria Macroalbuminuria
ACR 30–300 mg/g ACR > 300 mg/g
36 (3.14%) 4 (0.35%)
68 (6%) 5 (0.45%)
26 (2.3%) 8 (0.7%)
15 (1.3%) 5 (0.45%)
4 (0.35%) 5 (0.45%)
Microalbuminuria Macroalbuminuria
149 (13.0%) 27 (2.4%)
ronic Kidney Disease.
Table 3 Clinical characteristics of diabetic patients with any degree of CKD compared with diabetics with no CKD
no CKD CKD 1‘a’ CKD 2 CKD 3A CKD 3B CKD 4-5 P‘b’
FG ≥ 60 FG ≥ 90 FG 89-60 FG 59-45 FG 44-30 FG < 30
ACR < 30 ACR ≥ 30 CAC ≥ 30
N = 1145 (%) 826 (72.1) 40 (3.5) 73 (6.4) 133 (11.6) 60 (5.2) 13 (1.2)
Age (years) 64.9 ± 10.8 62.8 ± 10.7 67.6 ± 11.1 74.4 ± 8.6 75.2 ± 10.0 73.6 ± 10.6 0.001
Gender (Men) (n%) 511 (61.9) 25 (62.5) 47 (64.4) 63 (47.4) 36 (60.0) 7 (53.8) 0.053
BMI (kg/m2) 30.1 ± 5.2 30.4 ± 4.4 30.4 ± 5.3 30.7 ± 5.1 30.9 ± 6.0 30.1 ± 5.1 0.985
Abdominal waist circumference (cm) 99.8 ± 16.5 101.7 ± 11.7 99.4 ± 19.3 99.8 ± 19.8 100.4 ± 19.1 105.5 ± 14.1 0.950
Smoking (n%)
Yes 118 (14.3) 12 (30.0) 13 (17.8) 8 (6.0) 5 (8.3) 2 (15.4) 0.025
Ex-smoker 239 (28.9) 11 (27.5) 22 (30.1) 50 (37.6) 19 (31.7) 4 (30.8)
Never 469 (56.8) 17 (42.5) 38 (52.1) 75 (56.4) 36 (60.0) 7 (53.8)
HbA1C (%) 7.2 ± 1.2 7.8 ± 1.6 7.7 ± 1.3 7.1 ± 1.2 7.0 ± 1.0 7.9 ± 1.9 0.001
Duration of DM (years) 8.5 ± 6.5 9.5 ± 6.6 9.7 ± 7.4 11.1 ± 8.5 11.0 ± 6.9 11.7 ± 8.7 0.386
Glycaemia (mmol/L) 8.05 ± 3.20 8.84± 3.23 9.00± 2.79 7.90± 2.63 7.48± 2.98 7.88 ± 3.40 0.002
Hypertension (n%) 578 (70.0) 32 (80.0) 60 (82.2) 121 (91.0) 56 (93.3) 13 (100) 0.001
Systolic Blood Pressure (mmHg) 134.0 ± 12.5 136.9 ± 15.9 136.6 ± 15.1 135.9 ± 14.2 134.2 ± 14.1 134.5 ± 16.9 0.610
Diastolic Blood Pressure (mmHg) 77.8 ± 8.7 79.3 ± 9.9 76.3 ± 9.6 74.2 ± 10.0 72.8 ± 8.8 71.7 ± 6.6 0.003
Dyslipidaemia (n%) 555 (67.2) 27 (67.5) 52 (71.2) 97 (72.9) 37 (61.7) 8 (61.5) 0.638
Total cholesterol (mmol/L) 4.75 ± 0.95 4.94 ± 1.12 4.78 ± 0.99 4.59 ± 0.89 4.65 ± 1.11 4.30 ± 0.91 0.113
LDL cholesterol (mmol/L) 2.81 ± 0.81 2.95 ± 1.00 2.76 ± 0.79 2.67 ± 0.85 2.64 ± 0.94 2.21 ± 0.56 0.082
non-HDL cholesterol (mmol/L) 3.50 ± 0.91 3.75± 1.07 3.60 ± 1.01 3.31 ± 0.91 3.45 ± 1.08 3.22 ± 0.94 0.064
HDL cholesterol (mmol/L) 1.24 ± 0.33 1.19 ± 0.33 1.18 ± 0.26 1.28 ± 0.43 1.17 ± 0.34 1.07 ± 0.25 0.244
Triglycerides (mmol/L) 1.63 ± 0.94 1.88 ± 0.94 1.89 ± 1.21 1.76 ± 1.03 1.90 ± 0.96 2.17 ± 1.07 0.477
Plasmatic creatinine (mg/dl) 0.8 ± 0.1 0.6 ± 0.1 0.9 ± 0.1 1.1 ± 0.1 1.5 ± 0.2 2.3 ± 0.5 0.001
‘a’ CKD (1, 2, 3A, 3B, 4–5) different stages of CKD ‘b’ P (Kruskall-Wallis test, Chi-squared test).
eGFR = estimated glomerular filtration rate. ACR = albumin-creatinine ratio. CKD = Chronic Kidney Disease. BMI = Body Mass Index. HbA1C = glycosilated
hemoglobin. eGFR = estimated glomerular filtration rate. LDL cholesterol = Low Density Lipoprotein cholesterol. HDL cholesterol = High Density
Lipoprotein cholesterol.
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patients with a eGFR > 60 ml/min/1.73 m2, 9.9% presented
albuminuria. In the study by Lou Arnal et al. [16], 34.5%
of DM2 patients presented some stage of CKD, 16.1% of
DM2 patients had albuminuria (14.3% microalbuminuria
and 1.8% macroalbuminuria), and 9.4% of the patients
with eGFR ≥ 60 ml/min/1.73 m2 had albuminuria. Vinagre
et al. [17] found a prevalence of 20% for RI and 16.7% for
albuminuria. In another study in Spain [8] the prevalence
off different types of renal disease in DM2 was: 34,1% for
any type of CKD, 22,9% RI and 19,5% for albuminuria. In
a study performed in primary care centres in the Nether-
lands, van der Meer et al. [18] observed that 27.6% of
DM2 patients had CKD and that 13.6% of these DM2
patients had albuminuria. Another study in the United
Kingdom [19] showed that 31% of diabetic patients had a
GFR < 60 ml/min/1.73 m2 and 37% of these patients had
albuminuria. Pugliese et al. [20] found that the prevalence
of RI was 18.7% and CKD 37.5% with the MDRD Study
equation. Penno et al. [21] observed that in patients withrenal impairment, as identified by an estimated glomeru-
lar filtration rate (eGFR) less than 60 ml/min per
1.73 m2, 56.6% were normoalbuminuric, 30.8% were
microalbuminuric, and 12.6% were macroalbuminuric. In
the United States Plantinga et al. [22] showed that 32.9% of
U.S population had CKD and that 19.4% of these patients
had albuminuria. In a study performed in Australia,
Thomas et al. [23] observed that 23.1% of DM2 patients
had a GFR < 60 ml/min/ 1.73 m2 and that 34.6% of these
patients had albuminuria (27.3% microalbuminuria and
7.3% macroalbuminuria). In a Japanese study, Ohta et al.
[24] found that 46% of DM2 patients had CKD and that
36.1% of DM2 patients had albuminuria, and this group
reported that 25.2% of these patients had a GFR below
60 ml/min/1.73 m2. A study performed in Thailand [25]
reported that DM2 patients in primary care con-
sults had an albuminuria prevalence of 37.2% (26%
microalbuminuria and 11.2% macroalbuminuria). In a study
performed in Shanghai, Jia et al. [26] reported that 29.6% of
DM2 patients had CKD and that 26.2% of these patients
















≥ 150 1.61 (1.03-2.53)
Duration of DM 2 (years) 1.02 (1.01-1.04)
Coronary heart disease 1.54 (1.04-2.28)
Heart failure 2.69 (1.64-4.40)
Peripheral vascular disease 2.71 (1.69-4.35)
(CKD compared with “no CKD”).
CKD = Chronic Kidney Disease. OR = Odds Ratio. CI = Confident Interval.
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macroalbuminuria). Different prevalence of renal impair-
ment and albuminuria among studies may due to the dif-
ferent methodology applied. Our study required that two
of three determinations of eGFR or/and UACR, in a
period of three or more months, should be presented
normal or altered values.
Early detection of CKD has important clinical im-
plications. It is well known that a diminished eGFR is
associated with increased global mortality and cardiovas-
cular episodes [2,27-29]. Different epidemiological studies
have demonstrated that increased UAE is an important
risk factor for CKD in DM2 patients. A meta-analysis of
these studies [30] has shown that increased UAE doubles
the cardiovascular morbidity and mortality risk. Moreover,
UAE values in the high range of normality even predict
cardiovascular and renal complications [1,31]. Patients
with DM2 and CKD have an elevated risk of cardiovascu-
lar and renal complications, thus requiring improved
intervention and control [32,33]. Albuminuria and mortal-
ity association is lineal in a logarithmic scale, and this risk
doubles in patients with microalbuminuria with UACR
levels within the optimal range independent of the eGFR
and presence of other classic CVRF [5]. In the HUNT II
study [34], the presence of albuminuria and reduced eGFR
was associated with an increased risk of cardiovascular
mortality. Astor et al. [35] reported that reduced eGFR andincreased UAE independently increases the mortality risk
for patients with CVRF, and the simultaneous occurrence
of reduced eGFR and increased UAE was associated with
an even higher risk. Our study found a high prevalence of
PVD, different studies have shown a high prevalent PAD
associated with microalbuminuria alone, reduced eGFR
alone, and both reduced eGFR and microalbuminuria
compared to those without microalbuminuria or reduced
eGFR [36,37]. The higher prevalence in men may be
related to the higher percentage of male smokers.
The present study had weaknesses and strengths. Al-
though all autonomous communities were represented
and efforts were made to ensure a representative distribu-
tion of the Spanish territory, this study was not a
population-based study. The investigators were not ran-
domly selected because only those willing to participate
were involved in the study. The majority of these inves-
tigators were part of the RedGDPS (Red de Grupos de
Estudio de la Diabetes en Atención Primaria de la Salud,
Network for the Study of Diabetes in Primary Health
Care). Thus, it was impossible to dismiss investigator-
related bias and which patients were included. Another
source of bias can come from the frequency of visits by the
patients. However, the fact that the results of the present
study were similar to other studies indicates that these
biases had little influence on the final data. Importantly, all
patients included in this study had to present normal or
altered eGFR and UACR values in two of three deter-
minations in a period of three or more months. If these
requirements were not met, new eGFR and UACR deter-
minations were required. The patients that did not fulfil
this requisite were excluded from the final analysis.
Conclusion
In conclusion, this study demonstrated that the prevalence
of CKD in a sample of 1145 DM2 patients in primary care
consults was 27.9%. A systematic determination of GFR
and UACR would contribute to an earlier diagnosis, thus
allowing intervention in early stages of the disease in
which treatment is more efficacious.
Abbreviations
UACR: Urine albumin-creatinine ratio; CKD: Chronic kidney disease;
CVRF: Cardiovascular risk factor; DM2: Type 2 diabetes mellitus;
eGFR: Estimated glomerular filtration rate; MDRD: Modification of diet in
renal disease; ESRD: End-stage renal disease; UAE: Urinary albumin excretion.
Appendix I
Study investigators
Alum Bou A, Angullo Martínez E, Arnaiz Arroyo J, Artola Menendez S, Avila
Lachica L, Barquilla García A, Barrot de la Puente J, Barutell Rubio L,
Belinchón Sánchez M, Benito Badorrey B, Bobe Molina I, Bosch Costabella R,
Buil Cosiales P, Carramiñana Barrera F, Carrillo Fernández L, Carrión Valero L,
Casaseca Garcia P, Colt Loredana C, Comas Samper J, Cuevas Lopez J, De la
Sen C, Díez Espino J, Domínguez Coello S, Domínguez Navarro D,
Egocheaga Cabello I, Ferrer Menduiña X, Franch Nadal J, García Aparicio JM,
Garcia Gallego F, García Soidán FJ, Garrido Redondo N, Gómez García C,
Gomez Gonzalez L, Gonzalez Pastor C, Granero Fernandez E, Grau Bartomeu
Rodriguez-Poncelas et al. BMC Nephrology 2013, 14:46 Page 7 of 8
http://www.biomedcentral.com/1471-2369/14/46J, Guruchaga Arcelus M, Gutiérrez Almarza M, Gutierrez Perez A, Hernandez
Monroy A, Hidalgo Ortiz M, Iglesias González R, Igual Fraile D, Llussà Arboix J,
Marín Becerra T, Martín Manzano JL, Martínez Sierra C, Massana Raurich A,
Massó Orozco J, Mata Cases M, Merino Pacho J, Millaruelo Trillo JM, Morales
Escobar F, Modroño Freire M, Monzon Guerra A, Muguruza Valdeolmillos J,
Mundet Tuduri X, Mur Marti T, Nogales Aguado P, Ortega Ríos FJ, Otero Serra
X, Otzet Gramunt I, Pascual De la Pisa B, Patitucci Gómez F, Pinto Rivero M,
Piulats Egea N, Pujol Martínez R, Quindimil Vázquez J, Robles Agüero E,
Rodero Nuño M, Rodríguez Poncelas A, Ruiz Tamayo I, Sagredo Perez J,
Sanchez Cabrero LG, Sangrós González FJ, Sanz Rebollo G, Sedano Garcia JI,
Serra Laguarta M, Serrano Martin R, Socias Buades I, Torres Baile JL, Trenchs
Rodriguez M, Ulibarri del Portillo J, Vazquez de Prada I, Vergara Fernández I,
Villaro Gabarros M.
Competing interest
The authors declare that there is no duality of interest associated with this
manuscript.
Authors’ contributions
AR-P, JD E and JGO contributed to the conception and design, ARP and JGO
analysed and interpred the data. All authors contributed to the drafting of
the article and gave final approval of the version to be published.
Acknowledgements
We thank RedGDPS for the support, all the researches who participed in the
study included in Appendix 1, and laboratories Boehringer Ingel (Germany)
and Lilly (USA) for funding the project. Laboratories Boehringer Ingel and
Lilly not involved in the study design of analysis of results.
Author details
1EAP Anglès, Girona, Spain. 2Unitat de Recerca IAS, Salt, Spain. 3EAP Raval
Sud, Barcelona, Spain. 4Unitat de Recerca Jordi Gol, Barcelona, Spain. 5EAP
Tafalla, Navarra, Spain. 6EAP El Carmel, Barcelona, Spain. 7EAP Salt, Girona,
Spain.
Received: 14 September 2012 Accepted: 12 February 2013
Published: 22 February 2013
References
1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al: Chronic
kidney disease as a global public health problem: approaches and
initiatives - a position statement from kidney disease improving global
outcomes. Kidney Int 2007, 72:247–259.
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al:
Kidney disease as a risk factor for development of cardiovascular
disease: a statement from the American heart association councils on
kidney in cardiovascular disease, high blood pressure research, clinical
cardiology, and epidemiology and prevention. Circulation 2003,
108:2154–2169.
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease
and the risks of death, cardiovascular events, and hospitalization. N Engl
J Med 2004, 351:1296–1305.
4. Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: effects on the
cardiovascular system. Circulation 2007, 116:85–97.
5. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde
M, Astor BC, Woodward M, Levey AS, de Jong PE, et al: Association of
estimated glomerular filtration rate and albuminuria with all-cause and
cardiovascular mortality in general population cohorts: a collaborative
meta-analysis. Lancet 2010, 375:2073–2081.
6. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al:
US renal data system 2010 annual data report. Am J Kidney Dis 2011,
57(1 Suppl 1):A8. e1-526.
7. Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, et al:
Direct all-cause health care costs associated with chronic kidney disease
in patients with diabetes and hypertension: a managed care
perspective. J Manag Care Pharm 2009, 15:312–322.
8. Coll-de-Tuero G, Mata-Cases M, Rodriguez-Poncelas A, Pepió JM, Roura P,
Benito B, Franch-Nadal J, Saez M: Chronic kidney disease in the type 2
diabetic patients: prevalence and associated variables in a random
sample of 2642 patients of a Mediterranean area. BMC Nephrol 2012,
13(1):87.9. Kramer CK, Leitão CB, Pinto LC, Silveiro SP, Gross JL, Canani LH: Clinical and
laboratory profile of patients with type 2 diabetes with low glomerular
filtration rate and normoalbuminuria. Diabetes Care 2007, 30:1998–2000.
10. National kidney foundation K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and stratification. Am J
Kidney Dis 2002, 39(2 Suppl 1):S1–S266.
11. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al:
Using standardized serum creatinine values in the modification of diet
in renal disease study equation for estimating glomerular filtration rate.
Ann Intern Med 2006, 145:247–254.
12. Marín R, Coca A, Tranche S, Rodríguez Mañas L, Abellán J, Moyá A:
Prevalence of renal involvement in a population of type II diabetics
followed up in primary care. Nefrologia 2002, 22:152–161.
13. Tranche Iparraguirre S, Riesgo García A, Marín Iranzo R, Díaz González G,
García Fernández A: Prevalence of “hidden” renal failure in the
population suffering from type-2 diabetes. Aten Primaria 2005,
35:359–364.
14. Rodríguez-Poncelas A, Quesada Sabate M, Coll De Tuero G, Caula Ros J,
Gelada-Batlle E, Gómez-Marcos MA, et al: Prevalence of occult chronic
kidney disease and associated variables in a population of patients with
type 2 diabetes. Med Clin (Barc) 2010, 134:239–245.
15. de Pablos-Velasco PL, Ampudia-Blasco FJ, Cobos A, Bergoñón S, Pedrianes
P: En representación del grupo de investigadores DIABIR. Estimated
prevalence of chronic renal failure among patients with type 2 diabetes
in Spain. Med Clin (Barc) 2010, 134:340–345.
16. Lou Arnal LM, Campos Gutiérrez B, Cuberes Izquierdo M, Gracia García O,
Turón Alcaine JM, Bielsa García S, et al: Prevalence of chronic kidney
disease in patients with type 2 diabetes mellitus treated in primary care.
Nefrologia 2010, 30:552–556.
17. Vinagre I, Mata-Cases M, Hermosilla E, Morros R, Fina F, Rosell M, Castell C,
Franch-Nadal J, Bolíbar B, Mauricio D: Control of glycemia and
cardiovascular risk factors in patients with type 2 diabetes in primary
care in Catalonia (Spain). Diabetes Care 2012, 35:774–779.
18. van der Meer V, Wielders HP, Grootendorst DC, de Kanter JS, Sijpkens YW,
Assendelft WJ, et al: Chronic kidney disease in patients with diabetes
mellitus type 2 or hypertension in general practice. Br J Gen Pract 2010,
60:884–890.
19. New JP, Middleton RJ, Klebe B, Farmer CK, de Lusignan S, Stevens PE, et al:
Assessing the prevalence, monitoring and management of chronic
kidney disease in patients with diabetes compared with those without
diabetes in general practice. Diabet Med 2007, 24:364–369.
20. Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Giorgino F, Cavalot F,
Pontiroli AE, Baroni MG, Morano S, Nicolucci A, Penno G: The chronic
kidney disease epidemiology collaboration (CKD-EPI) equation provides
a better definition of cardiovascular burden associated with CKD than
the modification of diet in renal disease (MDRD) study formula in
subjects with type 2 diabetes. Atherosclerosis 2011, 218:194–199.
21. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R,
Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S,
Nicolucci A, Pugliese G, Renal Insufficiency And Cardiovascular Events
(RIACE) Study Group: Clinical significance of nonalbuminuric renal
impairment in type 2 diabetes. J Hypertens 2011, 29:1802–1809.
22. Plantinga LC, Crews DC, Coresh J, Miller ER, Saran R, Yee J, et al: Prevalence
of chronic kidney disease in US adults with undiagnosed diabetes or
prediabetes. Clin J Am Soc Nephrol 2010, 5:673–682.
23. Thomas MC, Weekes AJ, Broadley OJ, Cooper ME, Mathew TH: The burden
of chronic kidney disease in Australian patients with type 2 diabetes
(the NEFRON study). Med J Aust 2006, 185:140–144.
24. Ohta M, Babazono T, Uchigata Y, Iwamoto Y: Comparison of the
prevalence of chronic kidney disease in Japanese patients with Type 1
and Type 2 diabetes. Diabet Med 2010, 27:1017–1023.
25. Krairittichai U, Potisat S, Jongsareejit A, Sattaputh C: Prevalence and risk
factors of diabetic nephropathy among Thai patients with type 2
diabetes mellitus. J Med Assoc Thai 2011, 94(Suppl 2):S1–S5.
26. Jia W, Gao X, Pang C, Hou X, Bao Y, Liu W, et al: Prevalence and risk
factors of albuminuria and chronic kidney disease in Chinese population
with type 2 diabetes and impaired glucose regulation: Shanghai diabetic
complications study (SHDCS). Nephrol Dial Transplant 2009, 24:3724–3731.
27. Pinkau T, Hilgers KF, Veelken R, Mann JF: How does minor renal
dysfunction influence cardiovascular risk and the management of
cardiovascular disease? J Am Soc Nephrol 2004, 15:517–523.
Rodriguez-Poncelas et al. BMC Nephrology 2013, 14:46 Page 8 of 8
http://www.biomedcentral.com/1471-2369/14/4628. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al:
Chronic kidney disease as a risk factor for cardiovascular disease and all-
cause mortality: a pooled analysis of community-based studies. J Am Soc
Nephrol 2004, 15:1307–1315.
29. Nag S, Bilous R, Kelly W, Jones S, Roper N, Connolly V: All-cause and
cardiovascular mortality in diabetic subjects increases significantly with
reduced estimated glomerular filtration rate (eGFR): 10 years’data from
the south tees diabetes mortality study. Diabet Med 2007, 24:10–17.
30. Dinneen SF, Gerstein HC: The association of microalbuminuria and
mortality in non-insulin-dependent diabetes mellitus. A systematic
overview of the literature. Arch Intern Med 1997, 157:1413–1418.
31. Rachmani R, Levi Z, Lidar M, Slavachevski I, Half-Onn E, Ravid M:
Considerations about the threshold value of microalbuminuria in
patients with diabetes mellitus: lessons from an 8-year follow-up study
of 599 patients. Diabetes Res Clin Pract 2000, 49:187–194.
32. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al:
Albuminuria and risk of cardiovascular events, death, and heart failure in
diabetic and nondiabetic individuals. JAMA 2001, 286:421–426.
33. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a
multifactorial intervention on mortality in type 2 diabetes. N Engl J Med
2008, 358:580–591.
34. Hallan S, Astor B, Romundstad S, Aasarød K, Kvenild K, Coresh J: Association
of kidney function and albuminuria with cardiovascular mortality in
older vs younger individuals: The HUNT II Study. Arch Intern Med 2007,
167:2490–2496.
35. Astor BC, Hallan SI, Miller ER, Yeung E, Coresh J: Glomerular filtration rate,
albuminuria, and risk of cardiovascular and all-cause mortality in the US
population. Am J Epidemiol 2008, 167:1226–1234.
36. O’Hare AM, Glidden DV, Fox CS, Hsu CY: High prevalence of peripheral
arterial disease in persons with renal insufficiency: results from the
national health and nutrition examination survey 1999–2000.
Circulation 2004, 109:320–323.
37. Baber U, Mann D, Shimbo D, Woodward M, Olin JW, Muntner P: Combined
role of reduced estimated glomerular filtration rate and
microalbuminuria on the prevalence of peripheral arterial disease. Am J
Cardiol 2009, 104:1446–1451.
doi:10.1186/1471-2369-14-46
Cite this article as: Rodriguez-Poncelas et al.: Prevalence of chronic
kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2
study. BMC Nephrology 2013 14:46.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
